HOME >> BIOLOGY >> NEWS
Virginia Tech researchers receive $450,000 award to model cell division

BLACKSBURG, Va., June 26, 2002 Cancer is a group of diseases involving misregulation of cell growth and division. The more we know about how cells grow and divide under normal circumstances, the better we will understand how things go awry in cancer cells.

For this reason, John Tyson, University Distinguished Professor of Biology at Virginia Tech, and Bela Novak, professor of biotechnology at the Budapest University of Technology and Economics, are developing mathematical models of the molecular mechanisms that control the way yeast cells grow and assume various shapes.

Their work is being supported by a $450,000 grant from the James S. McDonnell Foundation of St. Louis, Mo.

"Division and shape are important to yeasts because, by growing in specific directions, they are able to seek out viable environments and potential mates," Tyson said. "Understanding how yeast cells control these processes is important to us not only because of the cancer connection, but also because we are still very much in the dark about how genes regulate behavior in the broadest sense.

"While the genome project has provided a parts list of the cell, scientists need a schematic diagram of how all those parts hook together," Tyson said. "From the schematic diagram, we can write equations that govern the behavior of the control system, much like an electrical engineer can write equations for a circuit diagram. With these equations we can predict how a cell will behave under many different conditions."

Although a human cell is more evolved than a yeast cell, a human cell is made of the same sorts of parts that behave in the same way. It was found that "the molecular constituents of the cell cycle control system are functionally interchangeable between yeast and humans," Tyson said. "What we learn about cell division in yeast can be carried over to humans." From what they learn about the molecular mechanism of yeast cell growth and division, Tyson
'"/>

Contact: John Tyson
tyson@vt.edu
540-231-4662
Virginia Tech
26-Jun-2002


Page: 1 2

Related biology news :

1. Two Virginia Tech energy-related inventions win R&D 100 awards
2. Virginia Tech researchers to release findings on Smith River Project
3. Virginia Tech professor honored with DeLaval Award
4. Virginia Techs smelly corpse plant due to bloom Aug. 4
5. Virginia Bioinformatics Institute researcher advances fight against sudden oak death disease
6. Virginia Center for Coal and Energy Research helps implement global climate change initiative
7. Cell cycle research earns biologist Virginias top scientist award
8. Virginia Tech-led group receives third five-year international biodiversity grant
9. Virginia Tech researcher receives $1.8 million to study Arabidopsis genome
10. Virginia Tech and North Carolina State University to run Forest Nutrition Research Cooperative
11. Virginia Bioinformatics Institute central to Regional Center of Excellence

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Virginia Tech researchers receive award model cell division

(Date:10/22/2014)... Medicine® scientists helps explain how bipolar disorder affects the ... therapies to treat the mental illness. , Scientists ... method recognized with the 2014 Nobel Prize in ... from mice with bipolar-like behaviors. In the synapses (where ... structures with concentrated levels of ANK3 -- the gene ...
(Date:10/22/2014)... , Oct. 20, 2014  Leading identity analyst firm ... half of the world,s population will have a chip-based ... Europe . Asia , ... market accounting for more than 60% of all National ... Acuity,s report  -- "The Global National eID ...
(Date:10/19/2014)... in India over the last 30 years contributed ... growth during that time, according to a new ... Change ., "Energy access is fundamental to development: ... including education, communication, and health," says IIASA researcher ... increased energy access is widely agreed to be ...
Breaking Biology News(10 mins):Bipolar disorder discovery at the nano level 2Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Improved electricity access has little impact on climate change 2
(Date:10/25/2014)... , October 24, 2014 ... Corporation (NASDAQ: CYTR ), Vertex Pharmaceuticals Inc. ... ALXN ), Peregrine Pharmaceuticals Inc. (NASDAQ: ... research on these five companies can be accessed at: ... Thursday, October 23, 2014, ended on a positive note ...
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis ... specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today ... to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., ... for the treatment of diabetic gastroparesis and other GI ... successful Phase 2 trial of relamorelin for the treatment ...
(Date:10/22/2014)... WriteResult, LLC – a premier provider of ... a team of researchers from Yale University’s School of ... to provide electronic questionnaire data collection through use of ... in May, aims to evaluate the impact of a ... and participation in urban agriculture to impact their consumption ...
(Date:10/22/2014)... ROCKVILLE, Md. , Oct. 22, 2014   ... company developing novel pathogen-specific therapies for serious infections and ... Office has issued a Notice of Allowance for a ... product in its C. difficile program, SYN-004. This ... to SYN-004 in the U.S. and adds to the ...
Breaking Biology Technology:Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
Cached News: